JP2017509624A5 - - Google Patents

Download PDF

Info

Publication number
JP2017509624A5
JP2017509624A5 JP2016556709A JP2016556709A JP2017509624A5 JP 2017509624 A5 JP2017509624 A5 JP 2017509624A5 JP 2016556709 A JP2016556709 A JP 2016556709A JP 2016556709 A JP2016556709 A JP 2016556709A JP 2017509624 A5 JP2017509624 A5 JP 2017509624A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
antibody
patient
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016556709A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017509624A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/020564 external-priority patent/WO2015142668A1/en
Publication of JP2017509624A publication Critical patent/JP2017509624A/ja
Publication of JP2017509624A5 publication Critical patent/JP2017509624A5/ja
Pending legal-status Critical Current

Links

JP2016556709A 2014-03-17 2015-03-13 心血管リスクを低減させる方法 Pending JP2017509624A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201461954094P 2014-03-17 2014-03-17
US61/954,094 2014-03-17
US201462025400P 2014-07-16 2014-07-16
US62/025,400 2014-07-16
US201462043182P 2014-08-28 2014-08-28
US62/043,182 2014-08-28
EP15305293 2015-02-26
EP15305293.1 2015-02-26
PCT/US2015/020564 WO2015142668A1 (en) 2014-03-17 2015-03-13 Methods for reducing cardiovascular risk

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020097344A Division JP2020143156A (ja) 2014-03-17 2020-06-04 心血管リスクを低減させる方法

Publications (2)

Publication Number Publication Date
JP2017509624A JP2017509624A (ja) 2017-04-06
JP2017509624A5 true JP2017509624A5 (enExample) 2018-04-12

Family

ID=52648962

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016556709A Pending JP2017509624A (ja) 2014-03-17 2015-03-13 心血管リスクを低減させる方法
JP2022116854A Pending JP2022141868A (ja) 2014-03-17 2022-07-22 心血管リスクを低減させる方法
JP2024115429A Pending JP2024147744A (ja) 2014-03-17 2024-07-19 心血管リスクを低減させる方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022116854A Pending JP2022141868A (ja) 2014-03-17 2022-07-22 心血管リスクを低減させる方法
JP2024115429A Pending JP2024147744A (ja) 2014-03-17 2024-07-19 心血管リスクを低減させる方法

Country Status (14)

Country Link
US (2) US20150284473A1 (enExample)
EP (2) EP3119810B1 (enExample)
JP (3) JP2017509624A (enExample)
KR (3) KR20220157516A (enExample)
CN (3) CN106794244A (enExample)
AU (3) AU2015231713B2 (enExample)
CA (1) CA2942549A1 (enExample)
EA (1) EA039310B1 (enExample)
ES (1) ES2978990T3 (enExample)
HU (1) HUE066839T2 (enExample)
IL (1) IL304491A (enExample)
MX (1) MX380767B (enExample)
PL (1) PL3119810T3 (enExample)
WO (1) WO2015142668A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
CN108096209A (zh) 2009-06-15 2018-06-01 阿马里纳制药公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
MX385311B (es) 2011-01-28 2025-03-18 Sanofi Biotechnology Anticuerpos humanos frente a pcsk9 para su uso en métodos de tratamiento de grupos concretos de pacientes.
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
HUE069234T2 (hu) 2011-09-16 2025-02-28 Regeneron Pharma Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
KR20160024906A (ko) 2013-06-07 2016-03-07 사노피 바이오테크놀로지 Ｐｃｓｋ9의 억제제를 투여함에 의한 죽상경화증의 억제 방법
EP3068803B1 (en) 2013-11-12 2021-01-20 Sanofi Biotechnology Dosing regimens for use with pcsk9 inhibitors
EP3169710A1 (en) * 2014-07-14 2017-05-24 Amgen Inc. Crystalline antibody formulations
JP6912374B2 (ja) * 2014-07-16 2021-08-04 サノフィ・バイオテクノロジー 高コレステロール血症を有する高心血管リスク患者を処置するための方法
CN107206068A (zh) 2014-07-16 2017-09-26 赛诺菲生物技术公司 用于治疗杂合型家族性高胆固醇血症(heFH)患者的方法
WO2016046684A1 (en) 2014-09-23 2016-03-31 Pfizer Inc. Treatment with anti-pcsk9 antibodies
KR20240172758A (ko) 2015-08-18 2024-12-10 리제너론 파아마슈티컬스, 인크. 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체
JOP20190112A1 (ar) * 2016-11-14 2019-05-14 Amgen Inc علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
US10337070B2 (en) 2017-01-12 2019-07-02 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
BR112019020148A2 (pt) 2017-04-13 2020-05-05 Cadila Healthcare Limited peptídeo
EP3762026B1 (en) * 2018-03-06 2026-04-08 Sanofi Biotechnology Use of pcsk9 inhibitor for reducing cardiovascular risk
CN112839672A (zh) * 2018-07-02 2021-05-25 艾比中心有限责任公司 用于减少脂蛋白a形成以及治疗主动脉瓣硬化和主动脉狭窄的组合物和方法
EA202190547A1 (ru) * 2018-08-17 2021-04-27 Амарин Фармасьютикалз Айрлэнд Лимитед Способы снижения потребности в реваскуляризации периферических артерий у субъекта, получающего лечение статинами
MA51766A (fr) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
EP4054625A4 (en) * 2019-11-07 2026-01-07 Medimmune Llc Endothelial Lipase Antibodies for the Treatment of Cardiovascular Diseases
BR112022009189A2 (pt) 2019-11-12 2022-07-26 Amarin Pharmaceuticals Ie Ltd Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
PH12022551172A1 (en) * 2019-11-18 2024-02-19 Ad Pharmaceuticals Co Ltd Anti-pcsk9 antibody and use thereof
BR112022020753A2 (pt) * 2020-04-15 2022-12-20 Voyager Therapeutics Inc Compostos de ligação a tau
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
CN114848849B (zh) * 2022-04-25 2023-11-17 南方科技大学 Pcsk9蛋白抑制剂在治疗心血管疾病中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
MX385311B (es) * 2011-01-28 2025-03-18 Sanofi Biotechnology Anticuerpos humanos frente a pcsk9 para su uso en métodos de tratamiento de grupos concretos de pacientes.
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول

Similar Documents

Publication Publication Date Title
Yu et al. Expert consensus on the use of human serum albumin in critically ill patients
JP2017506626A5 (enExample)
Soran et al. Hypercholesterolaemia–practical information for non-specialists
Rienstra et al. Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial
Teramoto et al. Efficacy and safety of alirocumab in Japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with Statins–ODYSSEY JAPAN randomized controlled Trial–
JP2021515772A5 (enExample)
Farnier et al. Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: pooled analysis of eight ODYSSEY Phase 3 clinical program trials
JP2017160208A5 (enExample)
JP2025011161A5 (enExample)
JP2017503820A5 (enExample)
JP2017528427A5 (enExample)
JP2020002171A5 (enExample)
JP2016529255A5 (enExample)
Mercer et al. Diabetes mellitus and the heart
Ito Dyslipidemia: management using optimal lipid-lowering therapy
JP2012528796A5 (enExample)
JP2014516953A5 (enExample)
FI2981255T3 (fi) Empagliflotsiinin terapeuttiset käytöt
JP2019507781A5 (enExample)
JP2016538277A5 (enExample)
CN107922507A (zh) 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者
JP2017535551A5 (enExample)
JP7193455B2 (ja) 心血管状態におけるインスリンデグルデク
Coghlan et al. Selexipag in the management of pulmonary arterial hypertension: an update
JP2020502134A5 (enExample)